ArticleIrish journal of medical science2025
Prognostic value of elabela peptide on predicting major adverse cardiac events of NSTEMI patients in emergency department.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role and therapeutic potential of elabela in renal disease: from molecular mechanisms to clinical applications.Endocrine connections · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThis study aimed to investigate the effects of Elabela peptide (ELA) levels in non-ST-segment elevation myocardial infarction (NSTEMI) patients presenting to the emergency department (ED) with cardiac chest pain to investigate the efficacy of ELA in predicting major adverse cardiac events (MACE).
methodsOur single-center, prospective study involved NSTEMI patients admitted to ED between June 2023 and June 2024. Serum ELA levels were determined by enzyme-linked immunosorbent assay using commercial kits. The performance of the ELA in predicting MACE and discriminating the NSTEMI group was evaluated by the receiver operating characteristic (ROC) analysis and the area under the curve (AUC).
resultsA total of 119 patients participated in this study: 64 NSTEMI patients and 55 controls. There was a weak and statistically significant correlation between the high-sensitive cardiac troponin T value at admission and the ELA levels. The median ELA value of the group with and without MACE was 954 and 811 pg/ml, respectively. There was a statistically significant difference between these groups (p = 0.049). The ability of the ELA value to predict 30-day MACE was assessed using ROC analysis, yielding an AUC of 0.652 (95% CI 0.523-0.767). The optimal cut-off point for ELA based on the Youden Index was > 962 pg/ml (sensitivity: 48.84%; specificity: 90.48%; positive likelihood ratio 5.13; negative likelihood ratio 0.57).
conclusionsIn conclusion, we propose that ELA can assist in the early diagnosis of NSTEMI patients presenting to ED with chest pain and may be an effective and supportive biomarker for predicting MACE.
Indexed as
Identifiers
40810830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.